Status:
RECRUITING
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Lead Sponsor:
Revolution Medicines, Inc.
Conditions:
NSCLC (Non-small Cell Lung Cancer)
Non-Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
Detailed Description
This is a global, randomized, open-label, Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve progression free survival (PFS) or overall survival (OS) compared to docet...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
May 6 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2030
Estimated Enrollment :
420 Patients enrolled
Trial Details
Trial ID
NCT06881784
Start Date
May 6 2025
End Date
December 1 2030
Last Update
March 12 2026
Active Locations (129)
Enter a location and click search to find clinical trials sorted by distance.
1
Alabama Oncology
Birmingham, Alabama, United States, 35243
2
MemorialCare Long Beach Medical Center
Long Beach, California, United States, 90806
3
Yale University, Smillow Cancer Center
New Haven, Connecticut, United States, 06519
4
Florida Cancer Specialists & Research Institute - South
Fort Myers, Florida, United States, 33901